Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 3) Regulations 2024

• Jurisdiction: Ireland
• Year: 2024
• Citation: IR SI 162/2024

STATUTORY INSTRUMENTS

S.I. No.162of2024

Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 3) Regulations 2024

I, STEPHEN DONNELLY, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations:

1. (1) These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 3) Regulations 2024.

(2) The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2024” includes these Regulations.

2. In these Regulations-

“Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of 2003);

“Regulations of 2023” means the Medicinal Products (Prescription and Control of Supply) (No. 7) Regulations 2023 (S.I. No. 584 of 2023).

3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of 2023) to the Principal Regulations is amended-

(a) in column 5 of the entry for “Comirnaty 3 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Paediatric pack”, by deleting “Administered as a course of 3 doses of (0.2ml) each”,

(b) by substituting for column 5 of the entry for “Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)” the following:

“In accordance with the summary of product characteristics of the product administered and/or relevant guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.”,

(c) in column 2 of the entry for “Naloxone injection”, by deleting “1mg/ml”,

(d) in column 2 of the entry for “Naloxone Nasal Spray”, by deleting “1.8 mg”, and

(e) by inserting the following entry:

“

Medicinal Product	Form and presentation of product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration	Place of administration
Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
Comirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine	Concentrate for dispersion for injection.	Intramuscular injection	Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in infants and children aged 6...